安进Amgen Inc. (AMGN) 2007年年度报告「NASDAQ」.pdf

1、 2008 Amgen Inc.All rights reserved.MC39651Amgen Inc.One Amgen Center DriveThousand Oaks,CA 91320-Amgen 2007 Annual Report and Financial SummaryAmgen is a biotechnology pioneer with a mission to serve patients.Sector:BiotechnologyCore business:Human therapeuticsProducts:Aranesp(darbepoetin alfa)Enbr

2、el(etanercept)EPOGEN(Epoetin alfa)Kepivance(palifermin)Kineret(anakinra)Neulasta(pegfilgrastim)NEUPOGEN(Filgrastim)Sensipar(cinacalcet HCl)Vectibix(panitumumab)Amgen at a Glance2007$4.29 2006 3.90 2005 3.20 2004 2.40 2003 1.90“Adjusted”earnings per share(EPS)*04050603Cash flow from operations($in mi

3、llions)2007$5,401 2006 5,389 2005 4,911 2004 3,697 2003 3,56704050603Total revenues($in millions)2007$14,771 2006 14,268 2005 12,430 2004 10,550 2003 8,35604050603“Adjusted”research and development(R&D)expenses*($in millions)2007$3,064 2006 3,191 2005 2,302 2004 1,996 2003 1,62104050603*“Adjusted”EP

4、S and“adjusted”R&D expenses are non-GAAP financial measures.See page 6 for reconciliations of these non-GAAP financial measures to U.S.Generally Accepted Accounting Principles(GAAP).07070707Be science-basedCompete intensely and winCreate value for patients,staff and stockholdersBe ethicalTrust and r

5、espect each otherEnsure qualityWork in teamsCollaborate,communicate and be accountableAmgen ValuesAmgen MissionTo serve patientsDear Stockholders,2007 was not the year we expected.Amgen was challenged as never before across a broad front.Shareholder value suffered,top and bottom line growth slowed,a

6、nd we found it necessary to restructure and shrink the organization.There is another story about 2007 for Amgen that is equally true,and one I want to expand upon here without at all distancing ourselves from the difficult aspects of the year.At the beginning of 2007,we were still enjoying a long pe